

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 464 297 A1

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **90830307.6**(51) Int. Cl.⁵: **A61K 35/78, A61K 7/00,
C07F 9/10**(22) Date of filing: **05.07.90**(43) Date of publication of application:
08.01.92 Bulletin 92/02(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE(71) Applicant: **INDENA S.p.A.**
Via Ripamonti, 99
I-20141 Milano(IT)(72) Inventor: **Bombardelli, Ezio**
Via Ripamonti, 99
I-20141 Milano(IT)
Inventor: **Patri, Gianfranco**
via Ripamonti, 99
I-20141 Milano(IT)
Inventor: **Pozzi, Roberto**
via Ripamonti, 99
I-20141 Milano(IT)(74) Representative: **Bianchetti, Giuseppe**
Studio Consulenza Brevettuale Via Rossini,
8
I-20122 Milan(IT)(54) **Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them.**

(57) Complexes of lipophilic extracts from plants of *Krameria* or *Eupomatia* genus and of some neolignanes isolated from the same extracts with natural or synthetic phospholipids; said complexes proved to have antiradical, antibacterial and antimycotic activities, so as to be useful as novel active principles for preparing medicaments and cosmetics. Due to the antioxidant, antibacterial and antimycotic activities thereof they can be used as natural preservatives in pharmaceutical and cosmetic formulations.

EP 0 464 297 A1

The present invention relates to complexes of extracts from *Krameria triandra* Ruiz et Pav. and other plants of the *Eupomatia* genus, as well as some phenol constituents thereof of neo-lignane or nor-neolignane nature, with phospholipids; to the processes for the preparation of said extracts and complexes, and to pharmaceutical compositions containing them.

The extracts from roots of *Krameria triandra* had been used widely in the past as medicaments, thanks to both the astringent property thereof, due to the presence of Ratania-tannin, and the antiinflammatory, antidiarrhoeal and antibacterial properties connected with other components; some of those characteristics are reported on Martindale, "The extrapharmacopeia", 28th Ed. (1982) and on other documents (Canizzaro, Boll. Soc. Ital. Biol. Sperim., 1, 22, 1964; and V. Hoppe, Drogenkunde Bdl Walter De Gruyter ed., 1975).

Two components of neolignane nature have been described as sunscreens for possible cosmetic use (Stahl, Planta Med., 42, 144, 1981). The first remarks on the medicinal properties of said plant go back to the Peruvian people empiricism, which used the roots for the oral cavity hygiene ("raiz para los dientes"), which use spread rapidly also in other countries in more recent times.

British patent 2.184.353A claims the antibacterial and antimycotic properties of extracts from *Krameria triandra* and of some components, called Ratania-phenols, for which the use by the topical route is envisaged for the treatment of acne, dermatomycosis and decubitus ulcers attributable to infections caused by aerobic and anaerobic strains. A renewed interest in *Krameria triandra* derivatives came out from Italian preliminary searches, the results of which, related to the antibacterial and antimycotic activities, were reported in the 1st Int. Symposium on Organic Chemistry of Medicinal Natural Products, Shanghai, and also in a degree thesis at the University of Milan.

From the above cited literature data, the antibacterial and antimycotic activities turn out to be essentially related to Ratania-phenols of neolignane nature; said compounds showing in vitro a remarkable antimicrobial activity which, as we could ascertain, almost completely disappears after administration of the compounds by the systemic route, since the phenol groups easily undergo oxidation, or other enzyme degradations can occur. Topical treatments with total or purified extracts also show to a considerable degree the same drawbacks of the systemic route, thus decreasing the effectiveness of the active principles.

Now, it has surprisingly been found that, by reacting these substances with phospholipids in aprotic solvents, to generate the lipophilic complexes disclosed hereinafter, the same antimicrobial activities of the free active principles can be obtained in vitro, with a simultaneous remarkable improvement in the in vivo antimicrobial, antiinflammatory and antiradical activities.

In order to prepare the above mentioned complexes, either the main components of the Ratania-phenol class, such as Eupomatenoid 6 or the compound 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran, which is among the main responsables for the biological activity, or purified extracts standardized in these active principles have been used, the latter being prepared chiefly by extracting the roots with chlorinated solvents such as methylene chloride, chloroform, dichloroethane, etc. and partitioning the concentrate between an aliphatic alcohol and an aliphatic or aromatic hydrocarbon. Generally the roots are extracted with methylene chloride, the percolate is concentrated to small volume and the residue is dissolved in 90% aqueous methanol and counter-extracted with n-hexane; the methanol phase, after appropriate dilution with water, is counter-extracted with a chlorinated solvent which extracts the active principles; the chlorinated organic phase is concentrated to small volume and the residue is insolubilized with n-hexane.

According to a preferred object of the present invention, in order to maintain the stability of the active principles during the extraction processes, the finely ground roots are extracted with carbon dioxide under hypercritical conditions, working at a temperature of 40°C and under a pressure of 120 bars; after the extraction under said conditions, the vegetable material is further extracted with carbon dioxide added with acetone, at a temperature of 45°C and under a pressure of 200 bars; the residue from this second extraction, after evaporating off the gas, is dissolved in methylene chloride, dehydrated, decolorized on charcoal and insolubilized in hexane.

From the above prepared extracts, the single pure components can be isolated, using chromatography techniques on silica gel, working on the per se products or, preferably, on the acetyl derivatives thereof, which are subsequently deprotected under controlled conditions.

The above cited extracts contain about 50% Eupomatenoid 6 and 25% 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran, as determined by gas chromatography or by HPLC. These substances, at the pure state, and the extracts containing them have been tested in vitro for the antiradical, antibacterial and antimycotic activities thereof, both as the free compounds and as the complexes thereof, and in vivo for the antiinflammatory and antimicrobial activities.

The obtained data are reported in Tables I, II and III.

The in vitro antimicrobial activity (M.I.C. expressed in mcg/ml) was evaluated in agar culture medium

Isosensitest agar Oxoid on Gram-positive and Gram-negative microorganisms from both collection and hospital isolation; Difco blood agar was used for streptococci, whereas Sabouraud maltose agar Difco was used for yeasts, moulds and dermatophytes, by incubating the various inocula according to standard procedures. The results are reported in the following Table I.

Table I

Antimicrobial activity of *Krameria* active principles and of the related complexes.

Microorganism	M.I.C. mcg/ml					
	I	II	III	IV	V	VI
<i>Staphylococ.aureus</i> Smith	0.012	0.78	1.56	3.12	1.56	0.78
<i>Staphylococ.aureus</i> 9144	0.024	0.78	1.56	1.56	1.56	3.12
<i>Staphylococ.aureus</i> F2*G	50	0.78	1.56	3.12	1.56	3.12
<i>Staphylococ.aureus</i> 6538P	0.012	0.78	1.56	3.12	1.56	3.12
<i>Staphylococ.aureus</i> OSCB*	3.12	0.78	0.78	3.12	1.56	1.56
<i>Staphylococ.aureus</i> FBF*	0.78	0.78	1.56	1.56	1.56	1.56
<i>Streptococ.pyogenes</i> 68	0.012	0.39	0.78	3.12	3.12	1.56
<i>Streptococ.pyogenes</i> 68/24	0.012	0.39	0.78	3.12	0.65	0.65
<i>Streptococ.faecalis</i> 6057	0.19	1.56	3.12	3.12	6.25	6.25
<i>Streptococ.faecalis</i> 99/85	0.39	3.12	6.25	6.25	6.25	6.25
<i>Streptococ.salivarius</i> 71/24	0.78	6.25	0.78	12.5	1.56	12.5
<i>Streptococcus. mutans</i> 60/21	0.012	0.78	0.78	1.56	1.56	3.12
<i>Streptococ.pyogenes</i> 65/57	0.19	0.78	0.78	0.78	1.56	6.25
<i>Streptococ.mitis</i> 77/231	0.78	1.56	1.56	1.56	0.78	3.12
<i>Sarcinia lutea</i> 9341	0.012	0.39	0.78	0.39	1.56	3.12
<i>Escherichia coli</i> 120	0.39	>200	50	>200	100	100
<i>Salmonella typhi</i> 6/12	0.19	>100	25	>100	50	>100
<i>Salmonella enteritidis</i>	0.78	200	50	>200	100	>100
<i>Neisseria meningitidis</i>	0.012	1.56	0.78	1.56	1.56	3.12
<i>Klebsiella pneumonie</i>	>200	>200	12.5	>200	12.5	>100

Table I (continued)

Microorganism	M.I.C. mcg/ml					
	I	II	III	IV	V	VI
<i>Candida albicans</i> G1	3.12	6.25	25	6.25	6.25	>200
<i>Aspergillus niger</i>	6.25	6.25	12.5	6.25	12.5	100
<i>Trichophyton mentag.</i>	0.39	1.56	1.56	1.56	1.56	25
<i>Trichophyton tonsurans</i>	0.19	0.78	1.56	1.56	0.78	12.5
<i>Microsporum canis</i> L/55	0.78	1.56	0.78	3.12	1.56	12.5

Substances

I = ampicillin for bacteria and miconazole for fungi.

II = Eupomatenoid 6.

III = 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.

IV = Complex of Eupomatenoid with phosphatidylcholine.

V = complex of 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran with phosphatidylcholine.

VI = Standardized *Krameria* extract.

The antiinflammatory activity by the topical route was evaluated in the mouse by the Croton oil test, according to the procedures reported in Agents and Actions, 17, 347-49, 1985. The results are summarized in the following Table II.

Table II

Antiinflammatory activity of the Krameria extract, of the active components thereof and of the related complexes in the Croton oil test in the mouse, at the maximum edema (6 hours).

Substances	Dose/mcg/ear	Edema mg	% reduction
Controls	---	7.4±0.2	---
Eupomatenoid 6	56	1.5±0.2	78.5 **
	28	4.5±0.1	40.2
Ratania-phenol*	56	1.9±0.2	73.7 **
	28	4.7±0.2	34.8
Krameria extract	70	1.8±0.3	75.0 **
Phospholipid °	157	6.5±0.3	10.2
	78	6.2±0.2	14.0
Eupomatenoid/ complex 1M:1M	96	1.9±0.2	73.7 **
Krameria extr./ Complex 1p:2p(w/w)	105	1.6±0.3	78.2 **

* 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.

° Distearoylphosphatidylcholine.

°° P<0.01 Student t.

The antiradical activity was evaluated using DPPH as the competitor, according to procedures described in literature. Following Table III reports the obtained results.

Table III

Antiradical activity of a *Krameria* standardized extract
and of two components thereof.

Substances	Conc.mcgr/ml	% destroyed DPNH
Eupomatenoid 6	6.6	-75.7
	2.8	-40.8
Ratania-phenol*	6.6	-80.5
	2.8	-46.4
Krameria extract	10	-72.4
	5	-41.6
Quercetin	6.2	-68.2

* 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.

In order to prepare the complexes with phospholipids, pure soy phosphatidylcholine or standardized mixtures of vegetable phospholipids with titres from 90% to 100% or pure synthetic phospholipids having saturated or unsaturated acyl chains and choline or ethanolamine as the basic portion, were selected as the complexing agents.

The formation of said complexes is ascertained by means of ^1H -NMR, ^{13}C -NMR, ^{31}P -NMR spectroscopies and solubility tests. As regards solubility, substances which are insoluble in aprotic solvents such as aromatic hydrocarbons, become easily soluble after complexation; in the ^1H -NMR spectrum the signals of complexed substances undergo a strong broadening, so as they can no more be evidenced in the spectra; in the ^{13}C -NMR spectrum the signals of the complexed substance, as well as those of the choline and glyceryl portions of the phospholipid, can no more be recorded; the phosphorus nucleus itself undergoes a band broadening, which indicates it is involved in the complex formation; in both the ^1H and the ^{13}C spectra, substantially only the lipid chain signals appear, even showing some immobilization. The above data prove the interaction between the phospholipid polar head and the active sites of the complex, whereas the lipid chains are not involved, since they are free to rotate and can wind the complexed molecule giving it a marked lipophilia.

This winding clearly results in a particular steric configuration when the complex is dispersed in an aqueous medium, giving stability to the molecules themselves.

The complexes of the present invention are insoluble in water and cannot form in this medium, therefore associations of the same products with phospholipids or liposomal preparations thereof do not give the same biological results; the complexes of the invention, due to dipolarity reasons, in aqueous medium give rise to micellar microdispersions remarkably similar to the liposome structures. The novel structures according to the invention show, in comparison with the same structures in the free form, a different *in vivo* bioavailability which involves an increase in the specific activity as well as a longer lasting action by the topical route (skin and accessible mucosae).

For this class of substances, phospholipids are a selective carrier allowing the molecules to have both an improved crossing of the horny layer of the skin and a better interaction with cell and bacterial walls. The molecules in the free form are restored and retained in the action site for a longer time. The presence of a surfactant, i.e. the phospholipid, in the molecule, allows to obtain a higher adhesion of the product itself to the surfaces it comes into contact with. This aspect is of paramount importance in cosmetic and pharmaceutical formulations intended for the treatment of the oral cavity, in which contact times are of

course very short; the opportunity to increase the adhesion of the product to mucosae or to the tooth surface and to make the various molecules interact with cell structures is of basic practical importance and it is an object of the present invention.

The dosages of the complexes of the invention can range widely, depending on the intended therapeutic purposes, and they can vary from 0.001 to 1%. The complexes of the present invention can be incorporated in the traditional pharmaceutical forms, such as ointments, fluid and thick O/W or W/O emulsions, solutions, chewable tablets, dusting powders, or in form of plasters or medicated gauzes. Said preparations can be used in humans or in animals for the treatment of superficial infected inflammatory processes, in torpid sores and in all the phlogistic conditions of the oral cavity; more particularly, as far as the oral cavity is concerned, they are an effective protection against the formation of dental plaque, when administered in form of medicated toothpaste, collutory or gel. In the cosmetic field, said complexes can be used for the treatment of acne and as deodorant, antidandruff and personal hygiene products.

The following non limiting examples further illustrate the invention.

EXAMPLE 1

Preparation of a standardized *Krameria triandra* extract.

10 kg of finely ground roots of *Krameria triandra* are extracted 4 times under mild reflux and nitrogen atmosphere with 4 volumes of methylene chloride; the combined extracts are concentrated to small volume under normal pressure. The concentrate is taken up into 5 l of 90% aqueous methanol and the solution is extracted 3 times with 1.5 l of n-hexane; the hexane phase is discarded since it contains no active principles whereas the methanol phase is concentrated to 1.2 l; this concentrate is extracted 3 times with 1.5 l of methylene chloride. The hydroalcoholic phase is discarded, whilst the chloromethylene extracts are pooled and treated with 25 g of decolorant charcoal in the presence of anhydrous sodium sulfate as the dehydrating agent; the decolorized chloromethylene solution is concentrated to small volume and the concentrate is poured into 1.5 l of hexane, under strong stirring. The precipitate is filtered and dried under vacuum overnight at 40 °C, to obtain 300 g of a product containing about 50% Eupomatenoids and 27% 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran.

EXAMPLE 2

Preparation of Eupomatenoid 6 and 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran.

100 g of an extract prepared according to the procedures reported in Example 1 are chromatographed on a column containing 1.5 kg of silica gel, which has previously been equilibrated with a toluene/ethyl acetate 9:1 mixture, eluting the products with the same solvent mixture; the fractions showing a similar composition by thin layer chromatography are pooled and concentrated to dryness. The more abundant fraction, containing Eupomatenoid 6 (54 g) is crystallized from an hexane-isopropyl ether mixture, thus recovering the pure compound; analogously, the fraction containing the benzofuran derivative is crystallized so as to isolate also this compound, the physico-chemical and spectroscopical characteristics of which are the same as those reported in literature.

EXAMPLE 3

Preparation of a purified *Krameria* extract by means of carbon dioxide under supercritical conditions.

1.5 kg of finely ground roots of *Krameria* are extracted continuously in a suited reactor, fitted with heating and cooling mantle, with carbon dioxide under supercritical conditions, in two steps. A first step is carried out at a temperature of 35 °C and under a pressure of 110 bars; in the evaporator temperature and pressure are 25 °C and 50 bars, respectively. Two hours after, the extracted material is unloaded from the condenser and carbon dioxide containing 1.5% acetone is circulated in the extractor. The first extract, containing only lipophilic substances with no activity, is discarded, whereas the second extract is collected, which is obtained by increasing temperature to 45 °C and pressure to 200 bars. The collected extract in the condenser is dissolved in isopropyl ether, the solution is dried over sodium sulfate and subsequently concentrated to small volume. The concentrate is poured into n-hexane : an abundant precipitate forms which, upon drying, weighs 46 g and has the same composition as that of the product obtained in Example 1, but it has a markedly lighter colour.

EXAMPLE 4

Preparation of the complex of the standardized extract of *Krameria* with soy phosphatidylcholine.

5 1.5 g of a purified *Krameria triandra* extract are dissolved together with 3 g of soy phosphatidylcholine in 30 ml of methylene chloride and heated to mild reflux for 2 hours; the chloromethylene solution is concentrated to dryness under vacuum at 30 °C until the solvent is completely evaporated off. The ¹H-NMR spectrum of the obtained product shows protonic signals at 0.8 ppm of aliphatic methyls of the lipid chains and CH₂ signals between 1.5 and 2.8 ppm, a very broad N-CH₃ signal at about 3 ppm, signals of
10 hydrogens on the double bond of aliphatic chains at 5.5 ppm and very broad, unresolved signals of aromatic protons of the *Ratania*-phenols at 6-8 ppm. In the ¹³C-NMR spectrum, the signals characteristics of *Ratania*-phenols between 102 and 135 ppm are absent or unresolved, and the signals of the carbons of phospholipid glycerin portion are also absent or extremely broadened, as well as those of the choline portion.

EXAMPLE 5

Preparation of the complex of Eupomatenoid 6 with soy phosphatidylcholine.

20 2.8 g (0.01 mole) of Eupomatenoid 6 are dissolved together with 7.8 g (0.001 mole) of pure soy phosphatidylcholine in 30 ml of dioxane free from peroxides and the solution is freeze-dried; 10.5 g of a white product are obtained, having m.p. 98-101 °C and spectroscopic characteristics in conformity with those of a complex. ¹H-NMR (C₆D₆ solution): strong broadening of aromatic protons at 6-8 ppm; broadening of the N-CH₃ signal at 3.3 ppm. The characteristic signals of lipid chains appear at 0.5-2 ppm. ¹³C-NMR
25 (C₆D₆ solution): absence of the signals of carbons of Eupomatenoid at 105-140 ppm and also of the lipid signals at 60-80 ppm.

EXAMPLE 6

30 Preparation of the complex of 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran with distearoylphosphatidylcholine.

2.78 g of 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran are dissolved in 50 ml of dioxane together with 7.95 g of distearoylphosphatidylcholine and heated under strong stirring for 3 hours at 50 °C, under argon
35 atmosphere. When dissolution is completed the whole is freeze-dried, to obtain a white-beige product having spectroscopic characteristics corresponding to those of a complex.

EXAMPLE 7

40 Preparation of a standardized extract of *Eupomatia laurina*.

10 kilograms of finely ground roots of *Eupomatia laurina* are extracted under weak reflux in a nitrogen atmosphere with 4 volumes of methylene chloride for four times and the pooled extracts are concentrated to a small volume at ordinary pressure. The concentrate is then dissolved in 2 l of 90 per cent aqueous
45 methanol and the resulting solution is extracted three times with 1.5 l of petroleum ether.

The petroleum ether phase not containing the active principles is discarded and the methanolic phase is concentrated to 0.9 l. The latter concentrate is diluted with 300 ml of water and extracted three times with 0.8 l of methylene chloride. The hydroalcoholic phase is discarded and the pooled methylene chloride
50 extracts are treated with 25 g of decolorizing charcoal in the presence of anhydrous sodium sulphate as dehydrating agent. The decolorized methylene chloride solution is concentrated to a small volume and the concentrate is poured under vigorous shaking into 1 l of hexane. After filtration of the precipitate and overnight drying under vacuum at 40 °C, 190 g are obtained of a product which contains as a major component Eupomatenoid 6.

EXAMPLE 8

Preparation of the complex between the standardized extract of *Eupomatia laurina* and soy-bean phosphatidylcholine.

20 g of purified extract of *Eupomatia laurina* are dissolved together with 40 g of soy-bean phosphatidylcholine in 300 ml of methylene chloride and heated under weak reflux for 2 h. The methylene chloride solution is concentrated to dryness under vacuum at 30 °C until the solvent has been completely removed. The ¹H-NMR spectrum of the final product shows protonic signals at 0.8 ppm originating from the aliphatic methyl group of the lipidic chains, CH₂ signals between 1.5 and 2.8 ppm, a very broadened N-CH₃ signal at around 3.4 ppm, signals from hydrogens on double bonds of aliphatic chains at 5.5 ppm and very broadened unresolved signals of the aromatic protons of phenols Eupomatenoide 6 like substances between 6.2 and 8 ppm. In the carbon spectra it is remarkable the absence or the lack of resolution of the typical signals of the Eupomatenoide like substances between 102 and 135 ppm and the absence or the extreme broadening of the signals of the carbons belonging to the glycerine and choline portions of the phospholipid. This complex is freely soluble in the chlorinated solvents and in the vegetal oils.

EXAMPLE 9

Preparation of a toothpaste containing the complex of the standardized *Krameria* extract.

100 g contain :

Complex of <i>Krameria</i> standardized extract	0.1 g
Sodium carboxymethyl cellulose m.v.	1.0 "
Sorbitol 70%	20.0 "
Glycerin	18.0 "
Colloidal silica	15.0 "
Titanium dioxide	2.5 "
Maize starch	2.0 "
Sodium laurylsulfate	2.0 "
Sodium laurylsarcosinate 30% s. a.	1.0 "
Flavouring composition	1.0 "
Purified water	q.s.to 100.0 "

EXAMPLE 10

Preparation of chewable tablets containing the complex of *Krameria* standardized extract.

Each 1 g tablet contains :

Complex of <i>Krameria</i> standardized extract	5.0 mg
Methyl cellulose m.v.	2.0 "
Colloidal silica	8.0 "
Magnesium stearate	10.0 "

	Mannitol	250.0 "
	Glycamil (monoammonium glycyrrhizinate)	5.0 "
5	Flavours	20.0 "
	Saccharose (compressible)	700.0 mg

10

EXAMPLE 11

Preparation of a medicated cream containing the complex Eupomatenoid/phosphatidylcholine.

15 100 g of an O/W emulsion contain :

	Complex Eupomatenoid/phosphatidylcholine	0.1 g
20	PEG-8 C ₁₂₋₁₈ alkyl ester	10.0 "
	Glyceryl stearate and PEG-8 stearate	2.5 "
	Isopropyl myristate	7.0 "
25	Preservative	0.1 "
	Glycerin	5.0 "
	Perfumed composition	0.5 "
30	Purified water q.s.to	100.0 g

EXAMPLE 12

35

Preparation of an aqueous gel containing the complex of the Krameria standardized extract

100 g of gel contain :

40

	Complex of standardized Krameria extract	0.1 g
	PEG-6 caprylic/capric glycerides	10.0 "
45	Ethoxylated oleyl alcohol	5.0 "
	Carboxyvinyl polymer	1.5 "
	Preservatives	0.3 "
50	Perfumed composition	0.2 "
	Sodium hydroxide	0.3 "
	Purified water q.s.to	100.0 "

55

EXAMPLE 13

Preparation of a lipogel containing the complex of the Krameria standardized extract.
100 g of gel contain :

5	Complex of standardized Krameria extract	0.1 g
	PEG-45 dodecylglycole copolymer	4.0 "
	Hydroxystearate	4.0 "
10	Polyisoprene	37.5 "
	Isopropyl myristate	38.9 "
	Silicone oil 350 cps	3.5 "
15	Hydrogenated castor oil	3.5 "
	Colloidal silica	3.0 "
	Polysorbate 80	3.0 "
20	Perfumed composition	0.5 g

EXAMPLE 14

Preparation of a dusting powder containing the complex of the Krameria standardized extract.

100 g of powder contain :

30	Complex of Krameria standardized extract	0.1 g
	Colloidal silica	2.0 "
35	Micronized hydrogenated castor oil	49.0 "
	Maize starch	48.9 "

40 Claims

1. Complexes of lipophilic extracts from plants of Krameria or Eupomatia genus, with natural or synthetic phospholipids.
- 45 2. Complexes of Ratania-phenols with natural or synthetic phospholipids.
3. Complexes of Eupomatenoid 6 with natural or synthetic phospholipids.
- 50 4. Complexes of 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran with natural or synthetic phospholipids.
5. Complexes as claimed in the preceding claims, in which phospholipids are selected from soy phosphatidylcholine, soy phosphatidylethanolamine, natural phospholipids having titres from 90 to 100% and pure synthetic phospholipids with saturated or unsaturated acyclic chains, having ethanolamine or choline as the basic portion.
- 55 6. A process for the preparation of lipophilic extracts from plants of Krameria or Eupomatia genus, which process consists in using carbon dioxide under supercritical conditions as the extraction solvent and in subsequently evaporating off said solvent.

7. A process as claimed in claim 6, in which process roots of *Krameria triandra* Ruiz et Pav. are subjected to extraction.
8. A process as claimed in claims 6 and 7, in which process extraction is carried out at temperatures around 40 ° C and under pressures of about 120 bars.
9. A process as claimed in claim 8, in which process, after the first extraction, the material is subjected to a second extraction with carbon dioxide under supercritical conditions, at a temperature of about 45 ° C and under a pressure of about 200 bars.
10. A process as claimed in the preceding claims, in which process the obtained extract can subsequently be subjected to dehydration.
11. Pharmaceutical and cosmetic compositions having antiinflammatory, antibacterial, antimycotic and antiradical activities, containing as the active principles the complexes of claims 1-5.

Claims for the following Contracting States: SP, GR

1. A process for the preparation of complexes of lipophilic extracts from plants of *Krameria* or *Eupomatia* genus or of *Ratania*-phenols contained therein with natural or synthetic phospholipids characterized in that the lipophilic extracts or the *Ratania*-phenols are reacted with phospholipids in aprotic solvents.
2. A process according to claim 1 in which phospholipids are selected from soy phosphatidylcholine, soy phosphatidylethanolamine, natural phospholipids having titres from 90 to 100% and pure synthetic phospholipids with saturated or unsaturated chains, having ethanolamine or choline as the basic portion.
3. A process for the preparation of lipophilic extracts from plants of *Krameria* or *Eupomatia* genus, which process consists in using carbon dioxide under supercritical conditions as the extraction solvent and in subsequently evaporating off said solvent.
4. A process as claimed in claim 3, in which process roots of *Krameria triandra* Ruiz et Pav. are subjected to extraction.
5. A process as claimed in claims 3 and 4, in which process extraction is carried out at temperatures around 40 ° C and under pressures of about 120 bars.
6. A process as claimed in claim 5, in which process, after the first extraction, the material is subjected to a second extraction with carbon dioxide under supercritical conditions, at a temperature of about 45 ° C and under a pressure of about 200 bars.
7. A process as claimed in the preceding claims, in which process the obtained extract can subsequently be subjected to dehydration.



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 83 0307

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	EP-A-0 250 953 (INDENA) * the whole document * - - - -	6-7	A 61 K 35/78 A 61 K 7/00 C 07 F 9/10
A,D	GB-A-2 184 353 (SATO PHARMACEUTICAL COMPANY) * the whole document * - - - -	1-5,11	
A	EP-A-0 209 038 (INVERINI DELLA BEFFA) * the whole document * - - - -	1-5,11	
A	EP-A-0 275 005 (INDENA) * the whole document * - - - -	1-5,11	
A	EP-A-0 275 224 (INDENA) * the whole document * - - - -	1-5,11	
A	EP-A-0 283 713 (INDENA) * the whole document * - - - - -	1-5,11	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K C 07 F
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of search 04 March 91	Examiner FERNANDEZ Y BRANAS F
<div>CATEGORY OF CITED DOCUMENTS</div> <div>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention</div> <div>E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document</div>			

THIS PAGE BLANK (USPTO)